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I
n amembrane surrounding a blood cell, there lived a cytokine receptor. On either end of this
membrane, a portion sticks out and faces either the inside or the outside of the cell and
scientists have long debated how an extracellular signal (cytokine) translates into
transcriptional changes. Newly published research in Science1 challenges decades of dogma
by stating that cytokines facilitate receptor dimerization and goes on to suggest that the oncogenic
function of JAK2 may actually be the result of catalyzing dimer formation from the cytoplasmic
tail.
Decades of research in hematopoietic cell biology, and indeed entire laboratories, have focused
on the structure and function of cytokine receptors since cytokine signaling is responsible for the
majority of the decision-making in blood cell production (how much and what type of mature
blood cell should be made). Cytokines are considered to be the “go” signals in hematopoiesis and
dysregulation of cytokine signaling disturbs the homeostatic balance of blood cell production,
leading to a number of diseases ranging from various cytopenias through to full blown leukemia.
In the hematopoietic system, household names such as EPO, TPO, GM-CSF, GCSF and the
family of interleukins all bind Class I cytokine receptors that dimerise and signal through the JAK/
STAT pathway. In the early 1990s, a landmark paper emerged with a fairly straightforward model
of Class I cytokine receptor activation – a ligand binds and induces dimerization, thereby
permitting JAK molecules to cross-phosphorylate.2 Since these early experiments though,
prevailing wisdom has shifted to suggest that Class I cytokine receptors exist as pre-formed
dimers.3,4 Initially, this left a substantial question: “How does a ligand that binds a pre-formed
dimer on the outside of the cell actually induce the activation of JAK proteins on the inside of the
cell?” Theories emerged based on crystal structures, epitope binding assays, and cell line work –
making a fairly compelling case that the ligand did not induce receptor binding, but was rather
involved in stimulating conformational changes in the receptor that would allow activation of the
JAK molecules.4,5 These studies were nearly exclusively performed in non-living cells using
techniques that would irreversibly cross-link dimers, such as protein fragment complementation or
cysteine cross-linking.6,7 This amplified the chances of observing pre-formed dimers, but did not
provide a sense of their relative abundance or their behavior in a living cell.
The new research from Wilmes/Hafer et al drives a substantial wedge in the middle of the
pre-formed dimer theories by measuring cytokine receptor dynamics in living cells using dual-color
single-molecule fluorescence imaging in combination with post-translational cell surface labeling.
StudyingEPOR,TPOR,andGHR, this study showed that receptorswerepredominantlymonomeric
and randomly distributed in the inactive state. When ligand was added, rapid dimerization ensued,
which rather harks back to the initial Cunningham et al model of ligand-induced dimerization.
Of significant interest to the myeloproliferative neoplasm (MPN) community, JAK2 V617F
mutated cells were also tested using these state-of-the-art live cell imaging techniques. They first
observed that ligand-induced dimers were more common in the presence of JAK2 and remained
stable in the absence of the JAK2 tyrosine kinase domain. Intriguingly, the removal of both the
tyrosine kinase and the pseudokinase (PK) domain led to loss of dimer stability. This is of course the
location of the JAK2 V617Fmutation which is the most common mutation in theMPNs (>50% of
patients bear this single pointmutation) and suggests that the role of themutationmight be to induce
dimerization in the absence of ligand (and therefore result in the inappropriate signalling that drives
disease). Wilmes/Hafer et al then repeated their initial experiments in the absence of ligand with
mutant versus non-mutant cells and demonstrated that the V617F mutation led to ligand-
independent dimerization at 50% (TPOR), 25% (EPOR) and 10% (GHR) of themaximum levels of
dimerization. Thiswould appear to give support for a structural role of the PKdomain and also gives
a potential mechanism for how JAK2V617F-mutant cells are hypersensitive to both EPO and TPO.
If it turns out that ligand-induced dimerization is the key to enacting a Class I cytokine receptor
activation of JAK and diseases are driven by modulation of dimerization rates, this will have
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substantial implications for our understanding of both normal
and malignant hematopoiesis. Molecules that modulate dimer-
ization rates could be developed to counteract the pathogenic
effects of ligand-independent signaling or could be used to
stimulate the production of specific cell types outside the body for
therapeutic purposes.
This is an exciting paper – it challenges a currently held
dogma with a potentially disruptive technology. At the very
least it will inspire efforts on both sides to work out the exact
mechanism of JAK activation in relevant in vivo models and
ideally in patient samples where aberrant JAK biology is
pathogenic. Perhaps most importantly, it challenges researchers
to understand the limitations of current experimental data and
to continue to try and destabilize long-held hypotheses about
“how things work”.
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